sanofi-aventis

Jul 22, 08
	NEW STORY
08:00 ET	Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Jul 21, 08
	NEW STORY
09:00 ET	Colorado Business Group on Health (CBGH) Releases Report on the State of Diabetes in Colorado
Jun 24, 08
09:42 ET	Unity Square in New Brunswick Receives Historic Contribution Through NJ Neighborhood Revitalization Tax Credit Program
Jun 19, 08
07:00 ET	Hall of Fame Baseball Legend Mike Schmidt Speaks Out for the First Time About Common Health Problem in Older Men
Jun 13, 08
08:00 ET	New STAY ON TRACK for Better Prostate Health Program Launches Father's Day Weekend at NASCAR Race
Jun 10, 08
12:00 ET	Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Jun 07, 08
13:10 ET	Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control
13:00 ET	New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
May 28, 08
02:02 ET	New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
May 27, 08
12:19 ET	Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
May 22, 08
09:15 ET	ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
May 21, 08
10:00 ET	Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
May 15, 08
13:10 ET	Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
12:28 ET	District Court Decision Affirmed in U.S. Lovenox(R) (enoxaparin sodium) Patent Infringement Case
May 13, 08
10:00 ET	Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
May 05, 08
17:00 ET	New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
May 02, 08
10:00 ET	Healthcare Coalition Launches Enhanced Website Offering Tools and Materials to Improve Patient Care During Transitions of Care
May 01, 08
08:00 ET	Sanofi-aventis Launches Teen Acne Awareness Program and Web Site
Apr 30, 08
11:15 ET	Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
Apr 17, 08
16:00 ET	Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
Apr 02, 08
08:00 ET	Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R)
Mar 20, 08
18:30 ET	Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
08:00 ET	'Wait, Educate Before You Self-Medicate'
Mar 15, 08
09:45 ET	New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
Feb 28, 08
08:00 ET	LPGA Pro, Jill McGill, Encourages Indoor and Outdoor Allergy Sufferers to Challenge Their Course
Feb 20, 08
12:00 ET	Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Feb 19, 08
08:00 ET	FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
Feb 12, 08
13:57 ET	Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
Jan 04, 08
08:00 ET	Ambien CR(R) (zolpidem tartrate extended-release) tablets CIV Improved Chronic Insomnia in Patients with Co-Morbid Generalized Anxiety Disorder
Dec 21, 07
08:00 ET	Employers Coalition for Healthcare Options (ECHO) Releases Report on the State of Diabetes in Alabama
Dec 13, 07
10:45 ET	Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
Dec 10, 07
10:58 ET	Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
08:00 ET	Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractioned Heparin (UFH)
Dec 07, 07
12:30 ET	New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
Nov 15, 07
15:39 ET	Sanofi-aventis Announces New Research Center in Oro Valley
Nov 10, 07
08:41 ET	New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
Nov 07, 07
12:00 ET	Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Nov 01, 07
07:00 ET	Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Oct 31, 07
11:28 ET	Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
Oct 24, 07
17:00 ET	Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
08:35 ET	New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
Oct 09, 07
10:30 ET	Sanofi-aventis US Chairman Tim Rothwell Addresses CMSA's Collaborative Practice Summit
Oct 02, 07
07:59 ET	New Prescription Allergy Treatment XYZAL(R) (Levocetirizine Dihydrochloride) Now Available for Fall Allergy Season
Oct 01, 07
08:00 ET	Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
Sep 05, 07
17:01 ET	The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
Aug 27, 07
08:00 ET	New 200 mg Vial for Eloxatin(R) (Oxaliplatin Injection) Offers Greater Convenience and Efficiency of Preparation
Jul 30, 07
07:00 ET	SoloSTAR(R), the First Prefilled Disposable Insulin Pen for Lantus(R), is Now Available in the United States
Jul 09, 07
11:16 ET	New Study Demonstrated That Extending Prophylaxis With Lovenox(R) (Enoxaparin Sodium Injection) to 5 Weeks Was More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients With Reduced Mobility
Jun 29, 07
13:08 ET	Rimonabant Regulatory Update in the United States
Jun 27, 07
08:00 ET	Taxotere(R) (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery
Jun 24, 07
18:00 ET	Apidra(R) Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin and Oral Antidiabetic Treatments (BOT)
Jun 23, 07
11:00 ET	Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus(R) Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones
Jun 21, 07
07:00 ET	Basketball Hall of Fame Coach Chuck Daly Creates Game Plan to Manage the Symptoms of Benign Prostatic Hyperplasia (BPH)
Jun 15, 07
08:00 ET	FDA Approves New Route of Administration for Rapid-Acting Apidra(R) Providing an Additional Treatment Option for Hospitalized Diabetes Patients with High Blood Sugar Levels
Jun 13, 07
18:25 ET	FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors
Jun 04, 07
18:30 ET	Updated Study Results Reinforce Survival Benefit of Taxotere(R) (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
09:00 ET	Eloxatin(R) (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
09:00 ET	The Eloxatin(R)-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
Jun 03, 07
18:00 ET	S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone
09:15 ET	FOLFOX4 (Eloxatin(R)-based Chemotherapy) After Surgery Improves Overall Survival in Patients With Early (Stage III) Colon Cancer
09:00 ET	Oxford Biomedica and Sanofi-Aventis Report new TroVax(R) Phase II Trial Results in Renal Cancer
08:30 ET	'My Child Matters' Program One-Year Report Shows Measurable Improvement in Cancer Care for Children in Developing and Newly Industrialized Countries
Jun 02, 07
12:00 ET	Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting
May 29, 07
11:27 ET	Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
May 18, 07
08:00 ET	FDA Approves Lovenox(R) (enoxaparin sodium injection) For the Most Severe Type of Heart Attack
May 08, 07
08:00 ET	Sopranos Star Aida Turturro Speaks out to Encourage Fellow Diabetes Patients to Take Control
May 07, 07
08:00 ET	New York Business Group on Health Releases Report on the State of Type 2 Diabetes in the Tri-State Area
May 03, 07
07:00 ET	sanofi-aventis: Full-year Guidance Raised on Good 2007 First-Quarter Results
May 01, 07
16:49 ET	FDA Approves Lantus SoloStar(R) - A New Prefilled Disposable Insulin Pen For Use With LANTUS(R) In People With Type 1 And Type 2 Diabetes
Apr 30, 07
08:00 ET	FDA Approves Lantus SoloStar(R) - A New Prefilled Disposable Insulin Pen For Use With LANTUS(R) In People With Type 1 And Type 2 Diabetes
Apr 20, 07
08:00 ET	The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Apr 02, 07
10:00 ET	State of Diabetes in Pittsburgh: Pittsburgh Business Group on Health Releases Report
Mar 29, 07
09:00 ET	National Transition of Care Coalition Continues to Build Support
Mar 26, 07
08:35 ET	Rimonabant USA: Update
Mar 25, 07
09:00 ET	Data Shows That Omission of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Medical Patients Is Frequent and Leads to Higher Risk of Deep-Vein Thrombosis (DVT)
Mar 16, 07
08:00 ET	Award-Winning Actress and Singer Lainie Kazan Travels Across the Country Urging Americans to Understand the Signs, Symptoms and Risk Factors for Deep-Vein Thrombosis (DVT)
Mar 13, 07
08:00 ET	Allegra(R) (fexofenadine hydrochloride) Oral Suspension Now Available to Help Manage Seasonal Allergy Symptoms In Children
Mar 12, 07
08:00 ET	Sanofi-Aventis Debuts AgingWithBeauty.com
Mar 06, 07
11:00 ET	Actor Cheryl Hines is Tired of Counting Sheep to Sleep ... and is Painting Them Instead
Feb 13, 07
01:30 ET	Sanofi-aventis 2006: In a Difficult Environment, Another Year of Growth in Adjusted EPS Excluding Selected Items
Feb 12, 07
11:45 ET	Sanofi-Aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Feb 07, 07
13:55 ET	FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
Feb 06, 07
10:30 ET	Tim Rothwell Appointed Chairman of Sanofi-aventis Group U.S. Pharmaceutical Activities
Feb 01, 07
08:00 ET	Sanofi-aventis Applauds New National Standards for Prophylaxis of Venous Thromboembolism in Surgical Patients
Jan 19, 07
07:42 ET	S-1 Oral Anticancer Agent Improves Patients' Survival In Adjuvant Gastric Cancer Trial Versus Surgery Alone
Dec 15, 06
18:44 ET	Sanofi-Aventis Statement Regarding U.S. FDA Joint Advisory Committee Recommendation for Ketek(R) (telithromycin)
Dec 12, 06
08:00 ET	New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Dec 08, 06
02:00 ET	Rimonabant Update in the United States
Dec 05, 06
06:35 ET	New Data Shows Rimonabant Benefited Patients with Type 2 Diabetes by Improving Blood Sugar Control, Reducing Weight and Acting on Other Cardiometabolic Risk Factors
Nov 16, 06
08:00 ET	Thirteen Leading Organizations Meet to Address Senior Healthcare Issues
Oct 31, 06
09:31 ET	Sanofi-aventis Announces Third Quarter Sales and Earnings for 2006:
Oct 30, 06
08:00 ET	New Study Shows Sculptra(R) (injectable poly-L-lactic acid), a Unique Class of Injectable for Cosmetic Use, Provides 13 Month Results
Oct 18, 06
14:48 ET	FDA Approves Allegra(R) (fexofenadine hydrochloride) Oral Suspension for Treatment of Seasonal Allergy Symptoms and Chronic Idiopathic Urticaria
07:55 ET	Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Oct 03, 06
09:00 ET	Coalition Founded to Address Crisis of Fragmented Senior Health Care
Sep 25, 06
15:26 ET	Sanofi-aventis and UCB Sign a Co-Promotion Agreement for Xyzal(R) in the United States
Sep 19, 06
08:00 ET	Dermik Laboratories Announces FDA Acceptance of Supplemental Filing Application for Sculptra(R)
Sep 07, 06
08:00 ET	The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(R)(Enoxaparin Sodium Injection) Vs. Unfractionated Heparin (UFH) in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention (
Sep 05, 06
10:02 ET	New Clinical Data Show Enoxaparin Significantly Reduced the Risk of Repeat Heart Attack and Stroke in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Aug 17, 06
14:19 ET	FDA Approves New Indication for PLAVIX(R) (clopidogrel bisulfate) Offering New Option for Patients With Most Severe Type of Heart Attack
Aug 02, 06
09:45 ET	Sanofi-aventis Announces First Half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis(1) Adjusted EPS(1) growth of 32.9%, or 16.1% excluding selected items(3)
Jul 28, 06
09:00 ET	Sports Legend Terry Francona Urges Americans to Understand the Signs, Symptoms and Risk Factors for Deep-Vein Thrombosis (DVT) in the National Educational Campaign, 'DVT Blood Clots: Know The Stats. Know Your Risk.'
Jul 12, 06
12:11 ET	New Data Support Long-Term Use of AMBIEN CRTM (zolpidem tartrate extended- release) Tablets C(IV) for up to 24 Weeks
Jul 03, 06
08:00 ET	Baseball Greats Team Up to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, 'DVT Blood Clots: Know The Stats. Know Your Risk.'
Jun 29, 06
14:56 ET	Sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Jun 20, 06
08:00 ET	New Data Reveals That Enoxaparin Results in Significant Cost Savings Compared to Unfractionated Heparin (UFH) in Treatment of in-Hospital Patients at Risk for Venous Thromboembolism (VTE)
Jun 10, 06
10:00 ET	New Study Shows an Innovative Mealtime Insulin Dosing Algorithm May Provide a Safe and Effective Alternative to Carbohydrate Counting for Patients With Type 2 Diabetes
Jun 06, 06
11:25 ET	Studies Evaluating Eloxatin-Based Regimens in Gastrointestinal Cancers Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Jun 01, 06
01:00 ET	Sanofi-Aventis General Meeting of Shareholders
May 31, 06
12:30 ET	New Eloxatin(R) and Taxotere(R) Data in Several Tumor Types to Be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 22, 06
08:00 ET	Sanofi-Aventis Announces Steps to Protect Access to Prescription Drugs for Low Income Medicare Patients
May 16, 06
08:00 ET	Star of the Batman(TM) Television Series Leads Crusade for Baby Boomers to Recognize Importance of Benign Prostatic Hyperplasia (BPH)
May 15, 06
08:00 ET	Sanofi-aventis to Develop healthFORWARD(TM) With Assistance From Innovatix
May 10, 06
08:00 ET	Sanofi-aventis Leases Additional Space in Cambridge to Support Future Expansion of its Research & Development Facility
May 05, 06
01:30 ET	Sanofi-aventis First Quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis(1); 52.8% growth in adjusted EPS(1) and 19.8% excluding selected items(3)
Apr 10, 06
17:04 ET	Appeals Court Rules in Sanofi-Aventis' Favor in the U.S. Lovenox(R) (enoxaparin sodium injection) Patent Infringement Case
08:00 ET	Sanofi-Aventis Purchases Additional Land in Oro Valley to Support Future Expansion of its Research & Development Facility
Mar 23, 06
13:07 ET	TAXOTERE(R) Receives U.S. FDA Approval For Use In Advanced Stomach Cancer
Mar 20, 06
16:00 ET	Statement Responding to Recent Media Reports Regarding Appropriate Use of AMBIEN(R) (zolpidem tartrate) CIV in the US
Mar 16, 06
11:36 ET	Agreement Between sanofi-aventis and Roche to Produce Shikimic Acid
Feb 28, 06
13:00 ET	Apidra(R) - a New Rapid-Acting Insulin Analog - Is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes
Feb 24, 06
07:30 ET	Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS(1); Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%
Feb 17, 06
19:59 ET	Sanofi-aventis Received from the FDA an Approvable Letter for Rimonabant for Weight Management and a Non Approvable Letter for Smoking Cessation
Feb 14, 06
16:00 ET	The Journal of the American Medical Association Publishes the RIO-North America Study
Jan 31, 06
02:00 ET	'My Child Matters': Launch of a Mobilization Campaign Against Childhood Cancer in Emerging Countries
Jan 30, 06
12:57 ET	Sanofi-aventis Posts Dynamic Growth in 2005 Full-Year Consolidated Net Sales: Up 9.3% on a Comparable Basis(1) Excellent Performance From Vaccines: Up 26.9% on a Comparable Basis(1) 2005 Adjusted Earnings(1) Guidance Raised Approval of Plavix(R) in Japan
Jan 18, 06
08:30 ET	FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack
01:30 ET	FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack
Jan 13, 06
08:01 ET	Pfizer to Purchase Sanofi-aventis Rights to Exubera(R) in Application of Change of Control Clauses
Dec 14, 05
08:59 ET	New Study Shows Burden of Venous Thromboembolism (VTE) for Americans
Dec 13, 05
14:30 ET	PLAVIX(R) (clopidogrel bisulfate) Recommended as Effective Cardiovascular Risk Reduction Treatment for Patients With Established Peripheral Arterial Disease (P.A.D.)
Dec 08, 05
12:28 ET	Interim Analysis of Phase III Study Shows TAXOTERE(R)-Based Regimens With HERCEPTIN(R) Significantly Improved Disease Free Survival in Women With Early-Stage HER2-Positive Breast Cancer
10:45 ET	Interim Analysis of Phase III Study Shows TAXOTERE(R)-Based Regimens With HERCEPTIN(R) Significantly Improved Disease Free Survival in Women With Early-Stage HER2-Positive Breast Cancer
Dec 02, 05
08:01 ET	FDA Grants Priority Review to Taxotere(R) for the Supplemental New Drug Application for Advanced Gastric Cancer
Nov 16, 05
17:00 ET	New England Journal of Medicine Publishes the RIO-Lipids Study
Nov 15, 05
11:53 ET	Interim Analysis of Phase III Study Shows TAXOTERE(R) (docetaxel)-Based Chemotherapy Regimens Combined with HERCEPTIN(R) (trastuzumab) Significantly Improved Disease Free Survival in Early-Stage HER2-Positive Breast Cancer
10:01 ET	Analysis From Several Clinical Studies Show Dronedarone Appears to Be Consistently Safe and Effective in Maintaining Normal Sinusal Rhythm and Ventricular Rate Control in Patients With Cardiac Arrhythmia
08:00 ET	Study Shows That Intra-Articular Hyaluronate Therapy Hyalgan(R) (sodium hyaluronate) Is Effective in Treating Chronic Shoulder Pain Due to Osteoarthritis
Nov 08, 05
01:00 ET	Sanofi-aventis Third Quarter 2005: Adjusted EPS(1) up 27.4%, Net Sales up 11.0% on a Comparable Basis(1)
Nov 07, 05
08:15 ET	Sanofi-aventis Group Announces New U.S. Headquarters Location
08:06 ET	New Data Show Long-Term (52 Week) Use of Alvesco(R) (ciclesonide) Had a Low Incidence of Oropharyngeal Side Effects in Patients with Mild-to-Moderate Asthma
Oct 07, 05
08:00 ET	AMBIEN CR(TM) Now Available in the U.S. for the Treatment of Insomnia
Sep 29, 05
15:00 ET	Hearing Date Set on Motion for Preliminary Injunction in Allegra(R) (fexofenadine HCl) Patent Infringement Case
09:00 ET	Sanofi-aventis Provides Relief to Hurricane Victims
Sep 20, 05
08:06 ET	FDA Accepts Filed Pre-Market Approval Supplement to Expand the Indication for Hyalgan(R) (sodium hyaluronate) to Include Shoulder Pain Due to Osteoarthritis
Sep 15, 05
08:01 ET	Interim Analysis of Phase III Study Shows TAXOTERE(R) (docetaxel)-Based Chemotherapy Regimens Combined with HERCEPTIN(R) (trastuzumab) Significantly Improved Disease Free Survival in Early-Stage HER2-Positive Breast Cancer
Sep 14, 05
08:00 ET	Study Finds Alvesco(R) (ciclesonide) Did Not Affect HPA-Axis Function in Patients With Moderate-to-Severe Persistent Asthma
Sep 12, 05
16:07 ET	Sanofi-aventis Group Enters Agreement With Prasco Laboratories to Market Generic Versions of Allegra(R) (fexofenadine HCl)
Sep 06, 05
08:02 ET	AMBIEN CR(TM) (Zolpidem Tartrate Extended-Release Tablets) CIV Receives FDA Approval for the Treatment of Insomnia
Aug 31, 05
01:30 ET	Sanofi-aventis Announces Strong Growth In 2005
Aug 18, 05
18:00 ET	Taxotere(R) Significantly Improves Survival Compared with paclitaxel in Women with Advanced Breast Cancer
Aug 02, 05
16:00 ET	Sanofi-aventis Issues Strong Support for Voluntary 'Guiding Principles' on DTC Advertising
Jul 27, 05
17:01 ET	ALLEGRA-D(R) 24 Hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets Now Available for Seasonal Allergy Sufferers
Jul 19, 05
01:04 ET	Sanofi-aventis Announces Strong Net Sales Growth in the First Half of 2005: 11.0% on a Comparable Basis(1)(2); Further Increase in Market Share(3) in the Second Quarter
Jun 30, 05
09:30 ET	Sports Legend Tony Gwynn Teams up with Former Baseball Champions to Raise Awareness of Deep-Vein Thrombosis (DVT) in the National Educational Campaign, 'DVT Blood Clots: Know The Stats. Know Your Risk.'
Jun 23, 05
01:30 ET	Rimonabant Accepted for Filing By the FDA
Jun 16, 05
11:44 ET	Lovenox(R) Patent Trial Update
Jun 13, 05
17:08 ET	Data Presented at ADA Showed that Basal Insulin Therapy with Lantus(R) Achieved Target Glycemic Control in Poorly Controlled Type 2 Diabetes
08:04 ET	Clinical Study Results Demonstrated Greater Flexibility With Mealtime Dosing of Apidra(R) When Compared to Regular Human Insulin
08:04 ET	Lantus(R) Add-on to Oral Monotherapy Therapy Showed Improved Glycemic Control in Type 2 Diabetes Patients Compared to Oral Actos Add-on to Oral Therapy
Jun 12, 05
18:00 ET	Rimonabant Study Shows Significant Improvements in HbA1c and Cardiometabolic Risk Factors in People With Type 2 Diabetes
Jun 09, 05
08:02 ET	Prospective Study Published in Diabetes Care Confirms Basal Therapy with Lantus(R) Improves Glycemic Control in Patients with Type 2 Diabetes Poorly Controlled on Prior Insulin Regimens
Jun 03, 05
12:47 ET	Sanofi-aventis Statement
May 31, 05
16:17 ET	Sanofi-aventis Annual General Meeting
May 25, 05
16:30 ET	Uroxatral(R) (alfuzosin HCl) Study Shows Improvement up to Two Years in Lower Urinary Tract Symptoms and Sexual Function in Men With Enlarged Prostates
May 24, 05
16:45 ET	New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP)
May 23, 05
11:17 ET	New Data Demonstrate Alvesco(R) (Ciclesonide) Significantly Reduces Oral Corticosteroid Use in Patients With Severe, Persistent Asthma
May 15, 05
11:45 ET	Taxotere(R) Regimen Demonstrates Significant Survival Benefit in the Treatment of Advanced Gastric Cancer
May 13, 05
01:00 ET	Sanofi-aventis 2005 First-Quarter Net Sales Growth Ahead of World Pharmaceutical Market Growth(1) at 11.9%(2) on a Comparable Basis
May 10, 05
16:00 ET	New Eloxatin(R) and Taxotere(R) Research to Be Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
01:30 ET	Rescheduling of the Pre-Trial Order Date in the United States Plavix(R) Litigation
Apr 20, 05
12:58 ET	Sanofi-aventis: Lovenox(R) Litigation in the United States
Apr 15, 05
07:15 ET	Sanofi-aventis Affirms Its Commitment to Access to Medicines in the 'Southern Countries', with a Policy of Tiered Drug Prices Geared to Populations Incomes
Apr 11, 05
16:47 ET	Sanofi-aventis Filing of the Form 20-F and 'Document de Reference'
08:15 ET	FDA Issues Approvable Letter for AMBIEN CR(TM) (Zolpidem Tartrate Extended Release) CIV for the Treatment of Insomnia
Apr 07, 05
14:24 ET	Sanofi-aventis Statement
Apr 01, 05
10:53 ET	Sanofi-aventis Concludes Euro 10 Billion in Medium-Term Credit Agreements With Its Banks to Refinance the Aventis Acquisition Financing Entered Into in April 2004
Mar 30, 05
12:22 ET	Rescheduling of the Pre-Trial Order Date in the United States Plavix(R) Litigation
Mar 24, 05
06:00 ET	Sanofi-aventis Joins the Fight Against Tuberculosis in South Africa
Mar 22, 05
14:33 ET	Court Grants Sanofi-Aventis' Request for Order of Prohibition in the Canadian Plavix(R) Litigation
12:00 ET	New Data Demonstrate Alvesco(R) (ciclesonide) Has a Low Incidence of Mouth- and Throat-Related Side Effects in Pediatric Asthma Patients
12:00 ET	New Data Demonstrate Alvesco(R) (ciclesonide) Significantly Improves Quality-of-Life for Patients with Mild-to-Moderate Asthma
Mar 11, 05
15:17 ET	Sanofi-Aventis Sues Novopharm for Patent Infringement in Canada
Mar 01, 05
01:00 ET	sanofi-aventis Reports Strong Growth of 18.2% in 2004 Adjusted(1) Proforma(1) EPS to 3.89 Euros Per Share
Feb 24, 05
15:47 ET	Creation of The sanofi-aventis European Works Council
08:35 ET	First Pilot Study to Show Benefit Using Hyalgan(R) (Sodium Hyaluronate) in the Treatment of Osteoarthritis of the Ankle
01:00 ET	Update of the Patent Litigation Schedule in the United States for Plavix(R)
Feb 22, 05
08:03 ET	CORRECTION: sanofi-aventis Announces Results of World Solidarity Day On Behalf of Southeast Asia January 25, 2005: 'Sharing in solidarity'
Feb 18, 05
02:30 ET	sanofi-aventis World Solidarity Day on Behalf of South East Asia, January 25, 2005: 'Sharing in solidarity'
Feb 17, 05
01:30 ET	sanofi-aventis Announces Commercial Availability of Twice-Yearly ELIGARD(R)
Feb 10, 05
17:30 ET	Appointments at the Communications Department of sanofi-aventis
Feb 03, 05
18:10 ET	sanofi-aventis Receives FDA Approval for New ELOXATIN(TM) Formulation
Jan 31, 05
01:30 ET	Two Studies Demonstrate Significant Benefit of ELOXATIN-Based Chemotherapy Combined With Bevacizumab in Advanced Colorectal Cancer
Jan 26, 05
08:27 ET	Sanofi-aventis 2004 Pro Forma Combined Net Sales(1): Up 10.0% on a Comparable Basis
06:02 ET	New Eloxatin(R) (oxaliplatin for injection) Research in Colorectal Cancer to Be Presented at the 2005 Gastrointestinal Cancers Symposium
Jan 25, 05
09:25 ET	Plavix(R) Patent
09:25 ET	Sanofi-aventis 'Solidarity Day' Offers Additional Aid, Assistance to Southeast Asia
Jan 19, 05
14:17 ET	Statement by sanofi-aventis
10:33 ET	The European Commission Imposes a Fine on Certain MCAA Producers
Jan 11, 05
01:30 ET	Taxotere(R) (Docetaxel) Receives 2 New European Approvals For Treatment of Breast Cancer
Jan 10, 05
10:32 ET	Sanofi-aventis and Regeneron Pharmaceuticals Reaffirm Development Commitment
10:30 ET	Aventis Pasteur, the Vaccine Division of the sanofi-aventis Group, Changes its Name to sanofi pasteur
Jan 06, 05
02:00 ET	Update of the Patent Litigation Schedule in The United States for Plavix(R)
Jan 03, 05
10:29 ET	Sanofi-aventis Provides Humanitarian Aid for South-East Asia
Dec 23, 04
10:03 ET	Approval of the Merger of Aventis With and Into sanofi-aventis
Dec 22, 04
09:20 ET	Sanofi-aventis to Reorganise Short-Term Financing
Dec 20, 04
09:37 ET	Sanofi-aventis Receives Patent Office's Notice of Allowance on Its Reissuance Application for Lovenox '618 Patent
Dec 09, 04
10:09 ET	Update of Patent Litigation Schedules in the United States for Plavix(R) and Lovenox(R)
Dec 07, 04
12:28 ET	First International Registry of Patients With Early Stage Breast Cancer Launched
Nov 29, 04
16:19 ET	ELOXATIN(TM) (Oxaliplatin for Injection) Based Therapy Combined With Bevacizumab (Avastin(TM)) Significantly Improves Survival in Patients With Advanced Colorectal Cancer
Nov 25, 04
15:06 ET	Proposed Relocation of Aventis' Headquarters From Strasbourg to Paris
Nov 09, 04
10:30 ET	Aventis, Part of the sanofi-aventis Group, Announced Termination of Its Agreements with Genta
Nov 05, 04
01:00 ET	ELOXATIN(TM) (Oxaliplatin for Injection) Receives FDA Approval for the Treatment of Colon Cancer Following Surgery (Adjuvant Treatment)
Nov 04, 04
15:57 ET	Possibility of Increase in Price of Mandatory Offer of sanofi-aventis to Shareholders of Hoechst AG to EUR 56.50 Per Hoechst Share
01:00 ET	European Union Approval for Taxotere(R) (docetaxel) in Prostate Cancer
Oct 26, 04
14:34 ET	Aventis Receives Approvable Letter from U.S. Food and Drug Administration for Alvesco(R) (ciclesonide) for Treatment of Persistent Asthma
Oct 21, 04
01:00 ET	Sales Momentum Maintained, Rapid Progress on Integration
Oct 14, 04
13:14 ET	Proposed Merger of Aventis into sanofi-aventis
Oct 13, 04
10:35 ET	sanofi-aventis Announces Bridgewater, NJ as U.S. Headquarters
Oct 08, 04
12:51 ET	Strengthening of the Alliance on Actonel(R) Between the sanofi-aventis Group and Procter & Gamble
Oct 01, 04
10:08 ET	sanofi-aventis Launches Its Mandatory Offer to the Shareholders of Hoechst Aktiengesellschaft
Sep 22, 04
14:34 ET	Appointments at the Communications Department of the sanofi-aventis Group
14:32 ET	New Appointments in the sanofi-aventis Group
Sep 17, 04
12:12 ET	Eloxatin(R) to Receive Expanded Indication in Europe for Early Stage Colon Cancer Treatment
Sep 16, 04
10:59 ET	Final Results of Sanofi-Aventis' Offer for Aventis
02:00 ET	The sanofi-aventis Group Thanks Its Team Members and Shareholders and Launches Its New Visual Identity
Sep 07, 04
10:25 ET	Sanofi-Aventis' Offer For Aventis; Subsequent Offering Period Has Expired
06:00 ET	Join Legendary Entertainer Harry Belafonte in New York City for Free Prostate Cancer Screenings During Prostate Cancer Awareness Month
Sep 06, 04
10:19 ET	Appointments of a Hundred Managers in 70 Countries in the Sanofi-Aventis Group
Sep 02, 04
15:11 ET	Agnes Garcia-Gibot is Appointed Director of International Internal Communications and Corporate Image for Sanofi-Aventis
Aug 31, 04
10:12 ET	Excellent First Half of 2004 for Sanofi-Synthelabo
Aug 30, 04
10:05 ET	Olivier JACQUESSON Becomes Head of Business Development
Aug 20, 04
17:00 ET	Birth of Sanofi-Aventis, The World's 3rd Largest Pharmaceutical Company, Ranking Number 1 in Europe
Aug 12, 04
09:56 ET	Broad Success of Sanofi-Synthelabo's Offer for Aventis
Aug 09, 04
09:21 ET	Sanofi-Synthelabo's Offer for Aventis Provisional Results of the Offers
Jul 31, 04
09:04 ET	Sanofi-Synthelabo's Offer for Aventis Tender Period Has Expired
Jul 29, 04
09:46 ET	FTC Clears Sanofi-Synthelabo's Offer for Aventis Shares
Jul 21, 04
01:00 ET	Very Strong Sales Growth in The First Half of 2004:
Jul 20, 04
14:47 ET	Teva Pharmaceuticals' ANDA Does Not Challenge the Product Patent for Avapro(R) (irbesartan)
Jul 15, 04
13:27 ET	The U.S. Federal Trade Commission's Bureau of Competition and Economics Has Completed Its Review of Sanofi-Synthelabo's Proposed Acquisition of Aventis
Jun 25, 04
09:55 ET	Sanofi-Synthelabo and Pfizer Conclude an Agreement on the Divestment of Campto(R) (irinotecan) Conditional Upon Completion of Sanofi-Synthelabo's Offer for Aventis
Jun 24, 04
10:07 ET	Sanofi-Synthelabo Annual General Meeting
Jun 23, 04
09:50 ET	Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers
Jun 22, 04
13:25 ET	Closing Date of Sanofi-Synthelabo's Offer on Aventis Postponed to July 30, 2004
09:40 ET	Draft Structure of SANOFI-AVENTIS Management Committee
Jun 14, 04
10:43 ET	Sanofi-Synthelabo's Offer for Aventis; Adjustment of Offer Terms on Approval of Aventis Dividend
Jun 04, 04
10:21 ET	New Indications for Arixtra(R) in the United States: The Treatment of Acute Deep Venous Thrombosis and Acute Pulmonary Embolism
Jun 02, 04
17:00 ET	ELOXATIN(TM) Study in New England Journal of Medicine Demonstrates Significant Benefit Over Standard Therapy in Early Stage Colon Cancer
Jun 01, 04
14:40 ET	Sanofi-Synthelabo's Offer for Aventis Expiration Date of Offers
May 26, 04
10:05 ET	Sanofi-Synthelabo's Offer for Aventis U.S. Offer Extended to Wednesday, June 30, 2004
09:38 ET	General Meeting of Sanofi-Synthelabo Shareholders Sanofi-Synthelabo's Offer for Aventis
May 17, 04
08:06 ET	Physicians Examine Rising PSA Following Definitive Therapy of Prostate Cancer in New Registry
May 14, 04
10:33 ET	Sanofi-Synthelabo's Shareholders Meeting and Offer for Aventis
May 05, 04
10:12 ET	Sanofi-Synthelabo's Offer for Aventis
May 04, 04
11:15 ET	Postponement of Sanofi-Synthelabo General Meeting of May 24, 2004
Apr 27, 04
09:52 ET	Approval by The European Commission of the Planned Acquisition of Aventis By Sanofi-Synthelabo
Apr 26, 04
09:30 ET	Agreement Between Sanofi-Synthelabo and Aventis to Create Sanofi-Aventis
Apr 22, 04
01:00 ET	Sanofi-Synthelabo: Sustained and Very Strong Sales Growth
Apr 19, 04
17:10 ET	Sanofi-Synthelabo Launches New U.S. Web Site
Apr 15, 04
02:30 ET	Distribution of Interim Dividend by Sanofi-Synthelabo to Its Shareholders
Apr 13, 04
12:25 ET	Sanofi-Synthelabo to Sell to GlaxoSmithKline Arixtra(R), Fraxiparine(R) and Notre Dame de Bondeville Plant
Apr 12, 04
07:02 ET	Sanofi-Synthelabo Commences U.S. Offer for Aventis
Apr 05, 04
15:53 ET	Sanofi-Synthelabo's Offer for Aventis
Mar 25, 04
12:30 ET	Alfuzosin 10 mg OD (Xatral(R) OD) Shows Beneficial Effect in Patients With Acute Urinary Retention
Mar 09, 04
09:16 ET	Two Pivotal Studies Indicate Acomplia(TM)(Rimonabant) Offers a Novel Approach to Cardiovascular Risk Management In Overweight/Obese People and Smokers
Feb 16, 04
01:00 ET	Sanofi-Synthelabo Outstanding 2003 Performance
Feb 04, 04
01:00 ET	Sanofi-Synthelabo to Acquire All of Taisho's 49% Interest in the Joint Venture Company Sanofi-Synthelabo-Taisho Pharmaceutical Co.
Jan 26, 04
12:34 ET	Sanofi-Synthelabo Announces Offer for Aventis's Shares
Jan 22, 04
01:00 ET	Sanofi-Synthelabo: Continued Strong Consolidated Sales Growth in 2003:
Jan 19, 04
01:00 ET	ELOXATIN(TM) Submitted in the United States and in Europe for the Adjuvant Treatment of Patients with Colon Cancer
Jan 16, 04
13:55 ET	Sanofi-Synthelabo Comments on Merger Rumors
Jan 12, 04
10:58 ET	ELOXATIN(TM) (oxaliplatin for injection) Approved in the United States For the 1st Line Treatment of Metastatic Colorectal Cancer
Jan 07, 04
17:28 ET	Sanofi-Synthelabo to Acquire All Interests in ARIXTRA(R), IDRAPARINUX and Other Oligosaccharides From Organon
14:16 ET	ELOXATIN(TM) Becomes a Cornerstone Therapy for the Treatment of Metastatic Colorectal Cancer in Europe
Dec 12, 03
13:23 ET	Sanofi-Synthelabo Strengthens Its Presence in France's Aquitaine Region
Dec 09, 03
14:57 ET	Publicis Group Wins the Worldwide Tender Offer Launched by Sanofi-Synthelabo
Nov 19, 03
01:30 ET	ARIXTRA(R) in the European Union: New Treatment Duration for the Prophylaxis of Venous Thromboembolic Events in Patients Undergoing Major Orthopaedic Surgery
Nov 03, 03
08:27 ET	Sanofi-Synthelabo Launches Uroxatral(R) in the United States for Effective Relief of the Signs and Symptoms of Enlarged Prostate
Oct 22, 03
01:00 ET	Sanofi-Synthelabo: Acceleration in Consolidated Sales Growth During Third Quarter:
Sep 30, 03
13:28 ET	Sanofi-Synthelabo Has Referred to the French Stock Market Regulatory Authorities (COB) Following a Financial Analyst's Report Concerning One of The Company's Compounds in Development
Sep 17, 03
01:30 ET	FDA Grants Priority Review to ELOXATIN(R) for the 1st Line Treatment of Metastatic Colorectal Cancer
Sep 02, 03
01:00 ET	-- Sanofi-Synthelabo 2003 First-Half EPS* Up 18.6% on a Reported Basis and 31.9% at 2002 Exchange Rates
Jul 22, 03
14:41 ET	Sanofi-Synthelabo Strong Growth in Consolidated Sales in the First Half of 2003
Jun 20, 03
16:45 ET	Statement Regarding Plavix(R) Litigation in the USA
Jun 18, 03
05:38 ET	New Indication for ARIXTRA(R) in the United States: Extended Prophylaxis of Deep Venous Thrombosis in Patients Undergoing Hip Fracture Surgery
Jun 16, 03
01:30 ET	Alfuzosin Approved by the Food and Drug Administration in the United States
Jun 02, 03
14:09 ET	Major Results on ELOXATIN(TM) (Oxaliplatin for Injection) Presented at the American Society of Clinical Oncology (ASCO)
May 29, 03
19:38 ET	FDA Cardiovascular & Renal Drugs Advisory Committee Votes That Alfuzosin is Not Associated With a Clinically-Relevant Prolongation of the QT Interval
May 19, 03
17:00 ET	Sanofi-Synthelabo Annual General Meeting
Apr 24, 03
01:30 ET	Sanofi-Synthelabo Strong Growth in Consolidated Sales in the First Quarter of 2003
Apr 22, 03
01:30 ET	Sanofi-Synthelabo Names Tim Rothwell as New Head of North America Operations.
Mar 12, 03
09:27 ET	Bristol-Myers Squibb Restatement
Feb 19, 03
18:09 ET	Sanofi-Synthelabo Net Profit Up 27.8% And Earnings Per Share Up 28.7% in 2002 (before exceptional items and goodwill amortization)
Jan 22, 03
10:57 ET	2002 Consolidated Sales Growth Substantially Higher Than the Market
Jan 17, 03
18:12 ET	Discontinuation of One of the Studies (ANDROMEDA) With DRONEDARONE
Dec 20, 02
08:56 ET	Hanspeter SPEK, Executive Vice President, Takes Responsibility for the Worldwide Operations of Sanofi-Synthelabo
Dec 12, 02
12:04 ET	Gerard Le Fur Appointed Senior Executive Vice President Of Sanofi-Synthelabo
Nov 18, 02
09:31 ET	Long-Term Treatment for One Year With Clopidogrel (Plavix(R)/Iscover(R)) And Aspirin Significantly Reduces the Risk of Death, Heart Attack and Stroke in Major New Study
Oct 23, 02
01:30 ET	Sanofi-Synthelabo Consolidated Sales Growth to End September 2002: + 13.2% on a Comparable Basis
Sep 05, 02
08:53 ET	Newly Approved ELOXATIN(TM), Chemotherapy Agent for Advanced Colorectal Cancer, Reaches Patients
Aug 12, 02
01:30 ET	ELOXATIN(TM), Chemotherapy for Advanced Colorectal Cancer, Receives Approval From the U.S. Food and Drug Administration
Jul 24, 02
01:30 ET	Consolidated Sales Growth for the First Half of 2002: 14.8% on a Comparable Basis
Jul 16, 02
19:12 ET	Elitek(TM) (rasburicase) Has Been Approved By the FDA in the United States
Jul 01, 02
01:30 ET	Sanofi-Synthelabo Announces Its Listing on the New York Stock Exchange
Jun 26, 02
10:19 ET	NDA Submission for Oxaliplatin in the United States In Advanced Colorectal Cancer
Jun 18, 02
10:30 ET	Sanofi-Synthelabo Announces Its Intention to List On the New York Stock Exchange
May 22, 02
16:36 ET	Sanofi-Synthelabo Shareholders' General Meeting
Apr 29, 02
14:30 ET	Fast Track Review for Oxaliplatin in the United States In Metastatic Colorectal Cancer
Apr 03, 02
11:36 ET	ANDA Notification From Dr. Reddy Laboratories
Mar 27, 02
10:47 ET	Arixtra(R) (Fondaparinux Sodium) Receives Marketing Authorisation In the European Union
Mar 25, 02
01:30 ET	Sanofi-Synthelabo Files a Complaint Against Apotex
Mar 12, 02
01:30 ET	CPMP Recommends Granting Marketing Authorization in the European Union for Irbesartan in the Treatment of Diabetic Renal Disease
Feb 28, 02
01:45 ET	FDA Decision Expands Use of Plavix(R) (clopidogrel bisulfate) - Now Indicated in Patients with Unstable Angina or Heart Attack (non Q-wave myocardial infarction)
Feb 19, 02
13:58 ET	Sanofi-Synthelabo Reports Strong Earnings Growth in 2001
Jan 24, 02
01:30 ET	Sanofi-Synthelabo Strong Growth in 2001 Consolidated Sales: Up 15.2% on a Comparable Basis
Jan 22, 02
12:52 ET	Sanofi-Synthelabo and IDM Sign a Collaboration Agreement in Cellular Immunotherapy to Develop and Market Immunological Treatments in Oncology
Jan 17, 02
01:30 ET	Sale of Sanofi-Synthelabo's Direct Interest in Laboratoires de Biologie Vegetale Yves Rocher
Jan 08, 02
17:23 ET	Sanofi-Synthelabo Transfers Rights to Gabitril(R) to Cephalon
Dec 20, 01
17:00 ET	Sanofi-Synthelabo and Pharmacia Finalize Plan for Transfer of U.S. Marketing Rights to Ambien(R) in 2002
01:30 ET	Sanofi-Synthelabo and Cephalon Sign a Collaboration Agreement For the Development and Marketing of Angiogenesis Inhibitors
Dec 10, 01
08:53 ET	Arixtra(R) (fondaparinux sodium) Has Been Approved by the FDA in the United States
Oct 24, 01
06:00 ET	Very Strong Growth in Consolidated Sales Through September 2001: Up 16.1% on a Comparable Basis
Sep 18, 01
20:53 ET	Ignoring a Form of Leg Pain Could Put You at Increased Risk for Heart Attack and Stroke
Sep 10, 01
02:30 ET	FDA Grants Priority Review to Supplemental New Drug Application Filed for Plavix(R) (clopidogrel bisulfate) by Sanofi-Synthelabo and Bristol-Myers Squibb
Aug 31, 01
02:00 ET	Strong Growth in Net Profit Attributable to the Group For the First Half of 2001: +47% (Before Exceptional Items and Goodwill Amortization)
Jul 25, 01
13:15 ET	Sanofi-Synthelabo: Accelerated Growth in Consolidated Sales During The First Half of 2001: Up 15.0% On a Comparable Basis
13:02 ET	Sanofi-Synthelabo Accelerated Growth in Consolidated Sales During The First Half of 2001: Up 15.0% On a Comparable Basis
Jun 11, 01
09:55 ET	Sanofi-Synthelabo to Boost U.S. Sales Force to About 2,000 Members
Jun 08, 01
09:20 ET	Sanofi-Synthelabo Strengthens Its Position in the United States By Increasing Its Rights on Avapro(R) (Irbesartan)
Apr 26, 01
17:17 ET	FDA Grants Priority Review to ARIXTRA(R) (Fondaparinux Sodium), for the Prevention of Venous Thrombo-Embolic Events Following Orthopedic Surgery
Mar 29, 01
09:21 ET	Fasturtec(R) (rasburicase) Receives Marketing Approval in Europe
Feb 20, 01
11:04 ET	Sanofi-Synthelabo 2000 Results; 58% Growth of Net Profit Attributable To the Group and 54% Growth of Net Profit Attributable to the Group Before Non-Operating Items and Goodwill Amortization
Jan 25, 01
03:00 ET